ADVERTISEMENT

Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Blue Chip Growth

Stock Report: "Ampio Pharmaceuticals, Inc." (AMPE) Report Updated: Oct 19, 2014 | Print This Page

Get more stock ratings by Louis Navellier

"Ampio Pharmaceuticals, Inc." (AMPE)

Rating: Sell Volatility: Moderate
Total Grade: D Industry: Pharmaceuticals
Competitors: ACT, SCLN, HSP, POZN

Stock Analysis

Rating: Monthly View

A
B
C
D
F
October November December January February March April May June July August September

Rating: Weekly View

This Week: D down no change
Last Week: D same no change
Two Weeks Ago: D up no change
service keys

"Ampio Pharmaceuticals, Inc."© quotemedia

Company Profile

Ampio Pharmaceuticals, Inc., a development stage pharmaceutical company, together with its subsidiaries, engages in the discovery and development of pharmaceutical drugs and diagnostic products to identify, treat, and prevent metabolic disorders, eye diseases, kidney diseases, acute and chronic inflammation diseases, and male sexual dysfunction. Its products include Optina, an orally administered compound that is in Phase II clinical trial for the treatment of diabetic retinopathy, diabetic macular edema, and hereditary angioedema; Vasaloc for the treatment of diabetic nephropathy; Zertane, an oral drug in late stage development that treats male sexual dysfunction for premature ejaculation; and Ampion, a non-steroidal biologic, aspartyl-alanyl diketopiperazine to treat chronic inflammatory and autoimmune diseases. The company is also developing a handheld oxidation-reduction potential diagnostic device for use at home or in healthcare facilities that will measure the oxidants/antioxidant balances in human blood and plasma. Ampio Pharmaceuticals, Inc. is headquartered in Greenwood Village, Colorado.

Recent News: "Ampio Pharmaceuticals, Inc."